Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cycloprodigiosin hydrochloride is a **stable red fluorescent pigment** isolated from the marine bacterium Pseudoalteromonas denitrificans and related species. It belongs to the prodigiosin family of **tripyrrole alkaloids** and is characterized by a cyclized prodiginine structure. Cycloprodigiosin hydrochloride exhibits **potent antimalarial activity**—with in vitro nanomolar efficacy against Plasmodium falciparum, surpassing chloroquine—and retains activity in vivo. It has also demonstrated **selective anticancer effects** in vitro against various cancer cell lines, as well as immunosuppressive and pro-apoptotic effects on T cells. Its biological activities are thought to arise from its ability to bind and transport ions across membranes and interaction with targets such as B-cell lymphoma 2 (Bcl-2) proteins, though its exact mechanism of action remains incompletely defined[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cycloprodigiosin hydrochloride.